Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 27, 2023

Nextwave Company Profile

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the competitive landscape for NEXTWAVE, and what generic alternatives to NEXTWAVE drugs are available?

NEXTWAVE has two approved drugs.

There are fifteen US patents protecting NEXTWAVE drugs.

There are thirty-four patent family members on NEXTWAVE drugs in fourteen countries.

Summary for Nextwave

International Patents:	34
US Patents:	15
Tradenames:	2
Ingredients:	1
NDAs:	2

Drugs and US Patents for Nextwave

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nextwave	QUILLIVANT XR	methylphenidate hydrochloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	202100-001	Sep 27, 2012	AB	RX	Yes	Yes	8,062,667	See Plans and Pricing	Y			See Plans and Pricing
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-002	Dec 4, 2015		RX	Yes	No	9,844,544	See Plans and Pricing	Y			See Plans and Pricing
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-001	Dec 4, 2015		RX	Yes	No	8,202,537	See Plans and Pricing	Y			See Plans and Pricing
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-003	Dec 4, 2015		RX	Yes	Yes	11,103,494	See Plans and Pricing	Y			See Plans and Pricing
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-003	Dec 4, 2015		RX	Yes	Yes	11,103,495	See Plans and Pricing	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Paragraph IV (Patent) Challenges for NEXTWAVE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Oral Suspension	5 mg/mL	➤ Subscribe	2013-08-02

International Patents for Nextwave Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Australia	2017202955	See Plans and Pricing
European Patent Office	2884961	See Plans and Pricing
Denmark	2428205	See Plans and Pricing
Russian Federation	2435569	See Plans and Pricing
Japan	5479086	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck

Johnson and Johnson

Harvard Business School

Boehringer Ingelheim

Colorcon

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.